See the DrugPatentWatch profile for Kisqali
How does Kisqali (ribociclib) work in the body?
Kisqali (ribociclib) is a cancer medicine used to treat certain hormone receptor–positive (HR+) and HER2-negative (HER2−) advanced or metastatic breast cancers. Its mechanism of action is to block CDK4 and CDK6—enzymes that help drive cell-cycle progression from the G1 phase into DNA synthesis (S phase). By inhibiting CDK4/6, ribociclib slows or stops the growth of cancer cells that rely on this cell-cycle pathway.
Why does blocking CDK4/6 help in HR+ breast cancer?
HR+ breast cancer growth is often supported by signaling that promotes cell proliferation. When CDK4/6 activity is inhibited, the downstream steps needed for cell division are disrupted, which limits tumor cell proliferation in cancers where the estrogen-driven cell-cycle program depends on CDK4/6.
What does CDK4/6 inhibition mean for patients (what changes during treatment)?
By targeting cell-cycle control rather than directly lowering estrogen, Kisqali works as a targeted therapy to reduce tumor growth rate. In practice, it is typically used in combination with endocrine therapy for HR+ disease, aiming to enhance overall control of hormone-driven tumor activity.
How is Kisqali’s mechanism different from endocrine therapy?
Endocrine therapy reduces or blocks estrogen signaling (the hormonal “upstream” driver in HR+ tumors), while ribociclib blocks the “downstream” cell-cycle machinery (CDK4/6) that helps translate proliferative signals into cell division. Combination therapy targets both parts of the growth pathway.
Sources
No sources were provided in the prompt. If you share the specific material you want me to use (or allow me to use external sources), I can cite them directly.